Join the BioNap Email List:

Monday, August 3, 2015

Nucynta Powers Depomed Past Horizon Bid

By Jason Napodano, CFA

- Second quarter results exceeded expectations, powered by strong initial results with Nucynta.

- On the second quarter call, management laid out plans for future Nucynta growth.

- Depomed's BOD rejected the $33 Horizon bid. I agree, and think the shares could be worth as much as $39 based on comp-analysis.

Please read the article on Seeking-Alpha: LINK

No comments:

Post a Comment